Home » Topics » Disease categories and therapies » Neurology/psychiatric

Neurology/psychiatric
RSS

Ampligen to be considered for orphan drug status in the E.U.

Aug. 7, 2000

First use of gene transfer to treat human neurodegenerative disease reported

Aug. 7, 2000

Tourette Syndrome symptoms improve with mecamylamine therapy

Aug. 7, 2000

Phase III efficacy results reported for nalmefene in stroke

Aug. 7, 2000

New compounds with opioid receptor affinity useful for pain treatment

Aug. 4, 2000

Moraxen approved in U.K. for severe cancer pain

Aug. 4, 2000

Levetiracetam shows promise as adjunctive therapy for partial onset seizures

Aug. 4, 2000

Anticonvulsants found to lower efficacy of leukemia chemotherapy

Aug. 4, 2000

D-Pharm's DP-b99 successfully completes phase I study as treatment of acute stroke

Aug. 4, 2000

New compounds interacting with 5-HT1A receptors useful for depression, etc.

Aug. 3, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 16, 2026
Gene replacement rescues autism-related phenotypes in mice
BioWorld Science
Autism spectrum disorder (ASD), developmental epileptic encephalopathies and other neurodevelopmental disorders are driven by the disruption of genes regulating...
For clonal hematopoiesis, epigenetics can be in driver’s seat
BioWorld Science
Clonal hematopoiesis (CH), where few blood stem cells produce a significant fraction of mature blood cells that are genetically identical, is partly an inevitable...
Elixiron’s enrupatinib shows upbeat interim phase II AD results
BioWorld
Elixiron Immunotherapeutics Inc. announced positive interim open-label phase II Alzheimer’s disease (AD) study findings of enrupatinib, an oral brain-penetrant...